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Abstract Human ECE-1 is expressed in four isoforms with
different tissue distribution and its mRNA and protein levels are
altered under certain pathophysiological conditions. To investi-
gate the transcriptional regulation of ECE-1, we studied the
regulatory region of ECE-1c, the major ECE-1 isoform. A
genomic clone comprising the complete human ECE-1 gene
including the putative ECE-1c-specific promoter was obtained.
Up to 968 bp upstream of the putative c-specific translation
initiation start codon and several serial deletion mutants were
subcloned into a reporter vector and transfected into endothelial
(BAEC, EA.hy926, ECV304) and epithelial (MDA MB435S,
MCF7) cells, showing very strong promoter activity in compar-
ison to the SV40 promoter and to the previously described ECE-
1a and 1b promoters. Transfection of serial deletion mutants
indicated two positive regulatory regions within the promoter
(3142/3240 and 3240/490) likely involved in binding GATA
and ETS transcription factors. RNase protection assay (RPA)
and 5P-RACE revealed multiple transcriptional start sites located
at about 3110, 3140 and 3350 bp. Site-directed mutagenesis
demonstrated a crucial role for the E2F cis-element for basal
ECE-1c promoter activity. Additionally, we found a correlation
between isoform-specific ECE-1 mRNA levels and corresponding
ECE-1a, 1b, 1c promoter activities.
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1. Introduction
Endothelin-converting enzymes (ECEs) play a key role in
the biosynthesis of endothelins because of their ability to gen-
erate endothelins by proteolytic cleavage of the biological in-
active precursors big ET-1, big ET-2 and big ET-3. Three
di¡erent ECEs (ECE-1, ECE-2 and ECE-3) have been de-
scribed [1^3]. All of them constitute membrane-bound, phos-
phoramidon-sensitive metallo-proteases. ECE-1 mainly con-
verts big ET-1 [1] and is synthesized for example in
endothelial and vascular smooth muscle cells [4,5]. ECE-2 is
predominantly expressed in the CNS and also preferentially
cleaves big ET-1, whereas the recently isolated ECE-3 pro-
cesses big ET-3, but not big ET-1. Human ECE-1 itself is
expressed in at least three di¡erent isoforms (ECE-1a, ECE-1b
and ECE-1c) [6^8] with similar enzyme kinetics but di¡erent
subcellular localization [8^10] and di¡erent tissue distribution
[5,11] : ECE-1c, which is mainly localized on the cell surface, is
expressed among other tissues in lung, heart, kidney, liver and
placenta and represents the major isoform with regard to the
level of mRNA expression [8]. ECE-1b is localized mainly
intracellularly which is consistent with the recently described
di-leucine motif in its N-terminus [12], whereas ECE-1a is
targeted to the cell membrane.
The genomic structure of ECE-1 is complex [5,8,11] (Fig.
1A): ECE-1c and 1b are speci¢ed by an isoform-speci¢c exon
that is spliced to exon 2 which is common to both isoforms.
ECE-1a is transcribed from an alternative promoter located
about 11 kb downstream of exon 2. The 5P-terminal part of
exon 3 is the ¢rst ECE-1a-speci¢c exon, whereas the 3P-termi-
nal part of this exon is common to all known ECE-1 isoforms.
Very recently a fourth ECE-1 isoform has been described [13]:
The d-speci¢c exon and its promoter are located in the small
(about 200 bp) genomic region between exon 1b and exon 2.
The developmental signi¢cance of ECE-1 is demonstrated
by studies of knockout mice [14]: Targeted disruption causes
craniofacial and cardiovascular abnormalities in addition to
congenital intestinal aganglionosis corresponding to human
Hirschsprung’s disease and an absence of epidermal melano-
cytes. The ontogenetic importance is further outlined by a
patient with a loss of function mutation of the ECE-1 gene
who shows similar symptoms [41].
There is also altered ECE-1 expression in adult pathophysi-
ology, e.g. neointima formation after balloon injury [39,40]
and pulmonary ¢brosis [15]. But little is known regarding
isoform-speci¢c ECE-1 gene regulation in vivo and in vitro:
Shao et al. [16] showed di¡erent regulation of ECE-1a, also
termed ECE-1L [11,17], and ECE-1b ( = 1K) in a rat liver
injury model and Corder et al. studied the expression of
ECE-1a, 1b and 1c in stimulated bovine aortic endothelial
cells [18]. In addition, we have recently demonstrated that
ECE-1a and ECE-1b are regulated by alternative promoters
and not by di¡erential splicing and that members of the ETS
family of transcription factors are involved in transcriptional
regulation of ECE-1a expression ([5,19,20] ; submitted data).
To gain further insight into isoform-speci¢c ECE-1 gene ex-
pression we have cloned and analyzed the promoter of the
major isoform, ECE-1c.
2. Materials and methods
2.1. Cloning of the ECE-1c-speci¢c promoter
Based on the sequence of human exon 1c we performed a nucleo-
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tide database search (GenBank) and obtained a human genomic chro-
mosome 1 clone (Acc. no. AL031728, GI 4491014) comprising the
whole ECE-1 gene including the putative ECE-1c-speci¢c promoter.
Up to 968 bp of the 5P-genomic region upstream of the putative c-
speci¢c translation initiation start codon were subcloned into the lu-
ciferase reporter vector pGL3basic (Promega, Madison, USA) via a
genomic PCR ampli¢cation using HotStarTaq (Qiagen, Hilden, Ger-
many) and the following primers: 5P-GTTGTCCTGAAGTCCC-
TGG-3P (sense), 5P-AGCTCGCGTGCTCCGCC-3P (antisense).
2.2. Construction of deletion mutants
PCR reactions were performed with a common antisense primer in
the 3P-terminal region of the putative c promoter region, directly 5P-
terminal of the c-speci¢c translation initiation codon, and several
di¡erent sense primers located at positions 389, 3142, 3217, 3240,
3409, 3490, 3739, 3885 (bp relative to the putative translation
initiation codon of the ECE-1c isoform). PCR products were sub-
cloned into the pGL3basic vector and the identities of the clones
were con¢rmed by sequencing.
2.3. Further reporter gene constructs
ECE-1a/pGL3basic and ECE-1b/pGL3basic promoter vectors were
constructed as previously published [5,19] and contain 1206 bp and
1278 bp respectively of the 5P-genomic regions. The TIE1/pGL3basic
vector contains 0.8 kbp of the published mouse Tie1 promoter (Acc.
no. S79346) [24].
2.4. Site-directed mutagenesis
Site-speci¢c mutations were created using a two-step PCR based
method as previously described [21]: In the ¢rst round two PCRs in
parallel were performed: The ¢rst one with a wild-type 5P-sense prim-
er (at position 3491: 5P-CGGGTCACACTCCAGTGCA-3P) and a
mutated antisense primer (5P-CGCGGCTTCGGAACCGAGTG-3P).
The second one with a mutated sense primer (complementary to the
mutated antisense primer; 5P-CACTCGGTTCCGAAGCCGCG-3P)
and a non-mutated 3P-antisense primer (directly 5P-terminal of the c-
speci¢c translation initiation codon, 5P-AGCTCGCGTGCTCCGCC-
3P). Reactions were performed using HotStarTaq (Qiagen, Hilden,
Germany) and human genomic DNA as template. PCR products
were puri¢ed via one QiaQuick column (Qiagen, Hilden, Germany)
and served as template for a further PCR reaction using the wild-type
5P-sense primer and the wild-type 3P-antisense primer from the ¢rst
round. The PCR product was subcloned into the luciferase reporter
vector pGL3basic. Successful mutagenesis was con¢rmed by sequenc-
ing.
2.5. Cell culture
Bovine aortic endothelial cells (BAECs) were isolated and cultured
as previously described [5,22,23]. The human endothelial cell lines
ECV304 (ECACC, Salisbury, UK) and EA.hy926 (a generous gift
from Dr. C.-J. Edgell) were cultured as previously described [5].
The human epithelial cell lines MCF7 (ATCC, Rockville, USA) and
MDA MB435S (Cell Lines Service, Heidelberg, Germany) were cul-
tured in RPMI 1640 medium (Biochrom, Berlin, Germany; supple-
mented with penicillin/streptomycin (Bio-Whittacker, Verviers, Bel-
gium), 10% fetal calf serum (Biochrom) and 1% L-glutamine
(GibcoBRL, Life Technologies, Eggenstein, Germany)) and Dulbec-
co’s modi¢ed Eagle’s medium (Bio-Whittacker; supplemented with
penicillin/streptomycin (Bio-Whittacker), 20% fetal calf serum (Bio-
chrom) and 2% L-glutamine (GibcoBRL)), respectively. Calu-6 cells
are purchased from ATCC (HTB-56).
2.6. Transfection experiments
Promoter luciferase constructs and control plasmids, pGL3 pro-
moter (SV40 driven) and pGL3basic (promoterless) (Promega), were
transfected using Lipofectine (GibcoBRL; for ECV304), Lipofect-
amine (GibcoBRL; for BAEC), Fugene-6 (Boehringer Mannheim;
for EA.hy926 and MCF7) and Lipotaxi (Stratagene; for MDA
MB435S) using 0.5^2 Wg plasmid per well. Cotransfection with pSV-
L-galactosidase control vector (0.5^1 Wg/well ; Promega) was carried
out to standardize for transfection e⁄ciency. Cells were harvested 48
h after beginning of the transfection procedure using reporter lysis
bu¡er (Promega). Luciferase and galactosidase activities were meas-
ured in a Lumat LB 9501 (Laboratorium Prof. Berthold, Bad Wild-
bad, Germany) using luciferase assay substrate (Promega) and galac-
ton/light emission accelerator (Tropix, Bedford, USA), respectively. A
construct-speci¢c transfection represents the mean value of six single
transfections.
2.7. Generation of template constructs for RNase protection assay
(RPA)
1. ECE-1 RPA: A 302 bp cDNA fragment of ECE-1c was generated
by PCR using human fetal heart cDNA (transcribed from the
respective poly-A RNA) as template (sense: 5P-GGAGCTGCGC-
GAAGCCGGGGCGG-3P ; antisense: 5P-GACACAAGCTTCGC-
TCAGGCACA-3P) and subcloned into pBluescript II KS(+) (Stra-
tagene).
2. RPA analysis of transcriptional start points: A genomic DNA
fragment (739 bp immediately upstream of the putative translation
initiation codon of the ECE-1c isoform) was subcloned into
pCR2.1 (Invitrogen) via genomic PCR. The identity of both sub-
cloned fragments was con¢rmed by sequencing.
2.8. RNase protection assay (RPA)
RPAs were performed with the RPA II kit and the MAXIscript T7
kit (both Ambion, Austin, TX, USA). Antisense RNA probes were
synthesized from linearized plasmids (1 Wg) in the presence of 5 Wl
[32P]CTP (20 mCi/ml, Amersham) and ATP, GTP and UTP (each
500 WM) in a total volume of 20 Wl using 20 U of T7 polymerase:
The ECE-1c construct for mRNA expression analysis was linearized
with XhoI yielding a transcript with a total length of 400 nt and a
gene-speci¢c length of 302 nt. The ECE-1c construct for analysis of
transcriptional start points linearized with NheI resulted in an anti-
sense RNA probe of 491 nt (total length)/394 nt (gene-speci¢c
length). The probes were gel puri¢ed by running the transcription
reactions on a 5% denaturating polyacrylamide gel and eluting the
appropriate bands overnight at room temperature in elution bu¡er
(supplied with the kit). The actual RPA reaction was performed
with about 3U105 cpm of the probe and approximately 30 Wg of
total RNA. After hybridization the digestion was carried out with
RNase A (2.5 U) and RNase T1 (8 U) for 60 min at 37‡C. Finally,
the samples were denatured for 4 min at 95‡C and separated by gel
electrophoresis on a 5% denaturating polyacrylamide gel. Century
marker template (Ambion) was used as size marker and transcribed
according to the manufacturer’s protocol. Gels were exposed on X-ray
¢lms (Kodak X-OMAT) or imaging plates (BAS-MP 2040S, Fuji)
with subsequent scanning of the latter by a phosphoimager (BAS-
1500, Fuji).
2.9. Rapid ampli¢cation of cDNA ends (RACE)
Reverse transcription (RT) was carried out using 5 Wg DNase-
treated total RNA, random hexamer primers (4 WM), RNasin (50 U;
Promega) and Superscript RT (200 U; Gibco) at 37‡C for 1 h in a
50 Wl reaction. 10 Wl of the resulting cDNA was tailed with dGTP
(2 nmol/Wl) using terminal transferase (0.4 U; New England Biolabs)
at 37‡C for 40 min. An aliquot of the tailed cDNA was used as a
template in a PCR with a poly-C primer (15 nt) and an antisense
primer in exon 2 (5P-CTGCAGGCCGTTGGGGTATGC-3P). After-
wards a second PCR with a nested antisense primer in exon 1c (5P-
CATAGCTCGCGTGCTCCGCCCCGGCT-3P) was carried out. The
resulting product was subcloned into the pCR2.1 vector (TA Cloning
Kit, Invitrogen) and sequenced.
2.10. Sequence analysis
The sequence was analyzed for cis-elements using the computer
program Transfac (version 3.5, Gesellschaft fu«r Biotechnologische
Forschung, Braunschweig, Germany; mirrored at http://www.motif.
genome.ad.jp; Heinemeyer, T., Chen, X., Karas, H. et al. (1999) Nu-
cleic Acids Res. 27, 318^322).
2.11. Statistical analysis
A two-tailed t-test was performed and statistical signi¢cance was
presumed at P6 0.05.
3. Results
3.1. Cloning of the human ECE-1c promoter
To clone the ECE-1c-speci¢c promoter a nucleotide se-
quence database (GenBank) was screened using the previously
published exon 1c sequence as a ‘probe’ in analogy to a clas-
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sical phage library screening. We obtained a human genomic
clone (Acc. no. AL031728, GI 4491014) comprising the com-
plete ECE-1 gene including the putative ECE-1c-speci¢c pro-
moter. Based on this cloned sequence it was possible to de-
termine the previously unknown length of the intron between
exon 1c and 1b, which totals 55 kbp (Fig. 1A). To further
ensure that the genomic region upstream of the putative exon
1c indeed represents the ECE-1c-speci¢c 5P-UTR, we per-
formed RT/PCR using a sense primer located 142 nucleotides
upstream of the ATG in exon 1c and an antisense primer
located in exon 2 of the ECE-1 gene. Sequencing of the ob-
tained product (data not shown) con¢rmed the existence of a
transcript containing 5P-UTR and coding sequence of exon 1c
directly attached to exon 2 (compare Fig. 1A).
3.2. Functional promoter analysis
Up to 968 bp upstream of the putative c-speci¢c translation
initiation start codon were synthesized by PCR using human
genomic DNA as template and subcloned into the luciferase
reporter vector pGL3basic. The full length construct (3968)
and serial deletion mutants which were generated by genomic
PCR using nested 5P-primers (at positions 389, 3142, 3240,
3490, 3739, 3885) were transfected into primary cultured
bovine aortic endothelial cells (BAECs) as well as the human
endothelial cell line ECV304 (Fig. 2A). To assess the relative
strength of ECE-1c promoter activity, an SV40 promoter driv-
en pGL3 plasmid was transfected as a positive control (Fig.
2A). Maximum promoter activity was detected following
transfection of mutant 3490 in BAECs (372-fold pGL3basic,
4.8-fold of SV40 promoter) and of mutant 3739 in ECV304
(111.8-fold pGL3basic, 8.9-fold of SV40 promoter). The two
shortest promoter constructs (389 and 3142) showed only
low relative luciferase activities (RLA) (3.5- and 5.5-fold
pGL3basic in ECV304). Extension of the construct to position
3240 resulted in a strong increase (P6 0.01) of RLA (49.5-
fold pGL3basic in ECV304). Potential cis-acting elements
identi¢ed in this region include consensus sequences for bind-
ing of the transcription factors E2F, SP1, AP2 and GATA
(Fig. 1B). 5P-extension of the ECE-1c promoter to position
3490 resulted in an additional increase (P6 0.01) in promoter
activity (95.8-fold pGL3basic in ECV304). This region con-
tains consensus sequences for GATA and ETS proteins (Fig.
1B). Further 5P-extension beyond position 3490 (constructs
3739, 3885 and 3968) did not show any signi¢cant changes
in promoter activity. With regard to species it is of interest to
note that the promoter constructs showed similar function in
Fig. 1. A: Organization of the human ECE-1 gene. The genomic structure of the 5P-terminal part of the human ECE-1 gene with exon-intron
boundaries and localizations of the alternative promoters is shown in the upper part. Exons 4 to 19, common to all isoforms, are not shown.
ECE-1 isoforms (1a, 1b and 1c), transcribed by di¡erent promoters, are shown in the lower part. (Data compiled from Schweizer et al. (1998),
Orzechowski et al. (1997) and unpublished experiments.) B: Human ECE-1c promoter sequence. Part of the genomic sequence (Acc. no.
AL031728; GI 4972242) with the major regulatory regions of ECE-1c promoter. Primer positions are double underlined, cis-elements are indi-
cated and exon 1c is marked by a box. The putative translational start codon of ECE-1c is represented in bold letters.
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the human endothelial cell line ECV304 and in primary cul-
tured BAECs (Fig. 2A).
To assess a possible cell-speci¢c regulation of the ECE-1c
promoter mutant 3739 was additionally transfected into the
human endothelial cell line EA.hy926 and into the human
epithelial cell lines MDA MB435S and MCF7 (Fig. 2B).
The ECE-1c promoter construct showed strong reporter ac-
tivity irrespective of endothelial or epithelial cellular origin.
To examine the role of the GATA consensus site at position
3226 two deletion mutants (3217 and 3240) were generated
which di¡ered by the GATA consensus sequence only. Dele-
tion mutant 3240, which contains the GATA consensus se-
quence, was 5.4-fold more active than mutant 3217 (Fig. 2C).
To determine the importance of the GATA and ETS consen-
sus sites at positions 3415 and 3422 respectively, deletion
mutant 3409 was created: 5P-extension to position 3490 in-
creased promoter activity by the factor 1.6 relative to 3409
(P6 0.01) (Fig. 2C).
3.3. Determination of transcriptional initiation points
Transcriptional start sites of ECE-1c mRNA expression
were determined by two independent methods, RNase protec-
tion assay (RPA) and 5P-RACE reaction. An antisense RNA
probe, which was based on genomic sequence, was used to
map the ECE-1c-speci¢c start sites in several di¡erent cell
types (Fig. 3A): Protected fragments approximately sized
110 bp (appearing as a double band), 140 bp and 350 bp
(less intensive) were detected in the RPA, corresponding to
transcriptional start sites at approximate positions 3110,
3140 and 3350 respectively, relative to the ‘ATG’ in exon
1c. Electrophoresis of the 3P-nested 5P-RACE products, using
Fig. 2. A: Promoter activity of serial deletion mutants in bovine
aortic endothelial cells and ECV304 cells. Relative luciferase activity
(RLA) is the ratio of the luciferase/galactosidase mean values of
each construct related to the promoterless reporter plasmid
pGL3basic [Luc (Construct)/Gal(SV40-LGal)/Luc (pGL3basic)/
Gal(SV40-LGal)]. Constructs were transfected into BAEC (left) and
ECV304 (right). An SV40 promoter driven pGL3 vector (‘SV40’)
served as control. Standard deviations related to Luc (pGL3basic)/
Gal(SV40-LGal) are indicated. B: Cell-speci¢c activity of the ECE-
1c promoter. ECE-1c promoter construct 3739 and an SV40 driven
pGL3 vector were transfected into EA.hy926, MCF7 and MDA
MB435S cells. RLA: Relative luciferase activity. C: Transfection of
ECE-1c promoter constructs. The ECE-1c reporter constructs 3142,
3217, 3240, 3409, 3490 (wild-type) and 3490 (mutated at the
E2F cis-element at position 3154) were transfected into MCF7 cells.
The RLA of the wild-type 3490 construct (non-mutated) was set to
100.
Fig. 3. A: Analysis of transcriptional start points by RNase protec-
tion assay (RPA). Total RNA was hybridized with an antisense
RNA probe (total length 491 nt; speci¢c length 394 nt (5P of the
‘ATG’ in exon 1c)). Lane 1, HUVEC (40 Wg); lane 2, Calu-6 (40
Wg); lane 3, EA.hy926 (40 Wg); lane 4, MCF7 (23 Wg); lanes 3/+,
yeast RNA with/without RNase. B: Analysis of transcriptional start
points by 5P-RACE. 5P-RACE was performed using HUVEC
mRNA and an antisense primer in exon 1c. Reaction products were
separated on agarose gel. Lane 1, 5P-RACE; lane 2, negative con-
trol ; lane ‘L’, 100 bp ladder.
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an oligo-C primer and an antisense primer immediately 5P of
the putative translational start codon in exon 1c, showed a
double band of about 130 bp (Fig. 3B). This corresponds to
transcript-speci¢c fragments about 20 bp shorter. Subcloning
and sequencing of the RACE products indicated speci¢city of
the fragments and 5P-ends at positions 3101 and 3106 bp
relative to the ‘ATG’, respectively.
To gain further insight into the mechanisms of basal tran-
scriptional regulation of the ECE-1c promoter, the consensus
sequence for Inr-associated protein E2F at position 3154
(Fig. 1B) was mutated by site-directed mutagenesis (5P-
gcgccgaa-3P to 5P-gTTccgaa-3P), which resulted in a dramatic
decrease in reporter activity by 79% (Fig. 2C).
3.4. Isoform-speci¢c ECE-1 promoter activities correspond with
transcript levels
To assess the ECE-1c promoter activity in comparison to
the previously characterized ECE-1a (also termed 1L) and
ECE-1b ( = 1K) promoters [5,19], isoform-speci¢c promoter
functions were analyzed in di¡erent cell types (Fig. 4A):
MCF7 cells showed only marginal activities of the ECE-1a
and ECE-1b promoters in comparison to the ECE-1c pro-
moter (Fig. 4A, left). In contrast, the ECE-1a and ECE-1b
promoters were active in ECV304 cells and reached 5% and
7.8% of ECE-1c promoter activity respectively (Fig. 4A,
right) ; the di¡erence in promoter activity, between ECE-1a
and 1b is signi¢cant (P6 0.01). Additionally the mouse Tie1
promoter was transfected into both cell types to compare the
ECE-1 promoters with another well characterized (almost en-
dothelium-speci¢c [22]) promoter, showing 11.8% activity of
ECE-1c promoter in MCF7 and 29.2% in ECV304. A possible
correlation of isoform-speci¢c ECE-1 promoter activities and
corresponding mRNA levels was addressed by ECE-1-speci¢c
RPA on MCF7 and ECV304 mRNA (Fig. 4B): MCF7 cells
express ECE-1c, but no ECE-1a or 1b, whereas ECV304 cells
express ECE-1c, some ECE-1b and no detectable ECE-1a.
4. Discussion
Here, we report cloning and basal characterization of the
human ECE-1c-speci¢c promoter localized approximately 55
kbp upstream of the recently cloned ECE-1b promoter [5,11].
Based on GenBank database searches, the 55 kbp sized intron
does not contain any other known gene. The ECE-1c pro-
moter shows extremely strong reporter activity in endothelial
and epithelial cells in comparison to the ECE-1a and ECE-1b
promoters as well as the recently published ECE-1d promoter
[13]. Strong c-speci¢c promoter activity is consistent with
ECE-1c as the major ECE-1 isoform regarding mRNA levels
[8,13].
The c-speci¢c promoter lacks a TATA-box, consistent with
multiple transcriptional start sites mapped by RPA in epithe-
lial and endothelial cells at approximately 110 bp, 140 bp and
350 bp upstream the translational start codon. The two adja-
cent transcriptional start points identi¢ed by RPA at about
3110 were further con¢rmed by 5P-RACE. Regarding the
start sites at about 3110 it is important to note that there
is a non-canonical CAAT-box at 3190, in appropriate dis-
tance of about 75 bp. There is also a consensus sequence
for the E2F binding at about 3150. This protein has been
implicated in cell proliferation control [25] and, importantly,
in mediating activation of initiator elements (Inrs) [26^28].
Inrs are located around the transcriptional start point and
can determine the start site in promoters without a TATA-
box. Therefore, it is likely that this E2F consensus element in
the TATA-box less ECE-1c promoter participates in tran-
scription initiation at 3140. This hypothesis is strongly sup-
ported by site-directed mutagenesis of the E2F consensus
which dramatically decreased ECE-1c promoter activity.
Focusing on consensus sites for regulatory transcription
factors in contrast to basal ones, reporter gene activities of
serial deletion mutants, especially the di¡erences for 3217 vs.
3240 and for 3409 vs. 3490, support the idea that the
GATA consensus sequence at 3226 and the overlapping
GATA and ETS consensus sites at 3415 and 3422 respec-
tively, are involved in binding GATA and, regarding the up-
stream region, GATA or ETS transcription factors. GATA
proteins (reviewed in [29^31]) constitute a family of zinc-¢nger
transcription factors that can be subdivided into two subfam-
ilies binding to the GAT(A/T) motif [32,33]. GATA-1, 2, 3
are mainly expressed in hematopoietic cells, whereas GATA-
4, 5, 6 show overlapping expression in the developing and
adult heart as well as in the gut. The importance of GATA
Fig. 4. A: ECE-1 isoform-speci¢c promoter activity. Luciferase pro-
moter constructs of human ECE-1a (31206/pGL3basic), 1b (31278/
pGL3basic) and 1c (3490/pGL3basic) were transfected into MCF7
(left) and ECV304 cells (right). The RLA of the ECE-1c construct
was equated to 100. The transfection of a mouse TIE1/pGL3basic
vector served as control. B: ECE-1 isoform-speci¢c gene expression.
mRNA levels of human ECE-1a, 1b and 1c in ECV304 and MCF7
cells were determined by RNase protection assay (RPA): Total
RNA was hybridized with an antisense RNA probe (total length
400 nt). A protected length of 302 nt corresponds to ECE-1c,
whereas ECE-1b is represented by a band of 264 nt. ECE-1a would
be expected at 177 nt. Lanes 1 and 2, MCF7 (30 Wg); lanes 3 and
4, ECV304 (30 Wg); lanes 3/+, yeast RNA with/without RNase;
lane L, molecular weight marker.
FEBS 23234 21-1-00
H. Funke-Kaiser et al./FEBS Letters 466 (2000) 310^316314
proteins for cardiac development is demonstrated by antisense
experiments [34] and the GATA-4 knockout which shows a
cardia bi¢da phenotype [35,36]. GATA factors are also impli-
cated in human congenital heart defects [37] and in neointima
formation after balloon injury [38], and these are pathophy-
siological conditions in which an involvement of ECE-1 was
shown [39^41]. Additionally, the preproendothelin-1 gene it-
self was the ¢rst non-erythroid target gene regulated in endo-
thelial cells by GATA-2 [42,43]. Furthermore there are con-
sensus sites for GATA proteins in the ECE-1a and 1b
promoters [5]. In this context, a transcriptional regulation of
ECE-1c by GATA factors in heart and endothelium appears
conceivable.
An alternative explanation regarding the regulatory region
between 3217 and 3240 involves the CAAT-box which over-
laps the GATA site (Fig. 1B). This box is in appropriate
distance to the start site at 3140, but to our knowledge no
interactions between CAAT-boxes and Inr elements or E2F
proteins have been described. Gel-shift experiments would be
necessary to clarify the role of GATA and E2F proteins in
ECE-1c regulation. As mentioned above, transcription factors
of the ETS family are also candidates for ECE-1c promoter
binding. ETS family members are expressed in endothelial
cells [44,45] and play a role in angiogenesis [46], neointima
formation [47,48] and endocardial cushion development
[49,50]. We previously reported data which suggest that the
ECE-1a promoter is regulated by ETS proteins in cultured
endothelial cells [20]. Whether this is also the case for the
ECE-1c promoter has to be further elucidated.
Another signi¢cant result is the correlation between iso-
form-speci¢c ECE-1 promoter activities and corresponding
mRNA levels in ECV304 and MCF7 cells (Fig. 4A, B):
MCF7 cells only express ECE-1c mRNA consistent with ne-
glectable promoter activities of the other isoforms. ECV304
cells additionally express ECE-1b mRNA and show a signi¢-
cant b-speci¢c promoter activity. The relative strong ECE-1b
signal in the RPA in comparison to the b-speci¢c promoter
activity (both related to ECE-1c) could be explained by the
fact that the protected fragment of 264 nt in our RPA not
only represents ECE-1b but also the recently published ECE-
1d [13] (the protected exon 2 is common to both isoforms).
These data indicate that the ECE-1 isoforms are regulated on
transcriptional level and that the promoter assays mirror tis-
sue mRNA expression.
This work in conjunction with the previously published
ECE-1 promoter studies [5,13,19] demonstrates that ECE-1
isoforms are not generated by di¡erential splicing of one com-
mon precursor but rather by alternative promoters. In gener-
al, alternative promoters have been implicated in spatial (cell-
speci¢c) and temporal (developmental) gene expression. In
addition they can contribute to di¡erent subcellular localiza-
tions and di¡erent quantities of isoforms [51,52]. All that ap-
plies to ECE-1: The isoforms show di¡erent cellular distribu-
tions, di¡erent subcellular localizations and seem to be
subjected to developmentally controlled gene expression
([8,13] and unpublished observations).
In conclusion, this work provides ¢rst insights into the tran-
scriptional regulation of the major ECE-1 isoform, which may
contribute to a better understanding of the regulation of the
endothelin system in developmental and under pathophysio-
logical conditions.
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